Table 1.

Baseline characteristics and patient status at randomisation

Baseline variables	Intervention (n = 36)	Control (n = 38)
Age, years, median	60	59
(1st, 3rd quartile; min–max)	(44, 69; 25–85)	(43, 72; 27–80)
Sex, male/female	21/15	26/12
Primary diagnosis, number of patients
Cardiovascular	8	5
Respiratory	3	9
Gastrointestinal	14	15
Renal	0	1
Trauma	3	1
Other	8	7
APACHE II score, median	20	23
(1st, 3rd quartile; min–max)	(11, 24; 0–31)	(17, 26; 0–38)
Charlson comorbidity index, median	1	1
(1st, 3rd quartile; min–max)	(0, 2; 0–5)	(0, 2; 0–7)
SOFA score for first 24 hours, median	7	8
(1st, 3rd quartile; min–max)	(5, 11; 2–16)	(5, 9; 1–16)
Time, hours from intubation to start of monitoring, median	4.0	4.9
(1st, 3rd quartile; min–max)	(2.1, 6.2; 1.0–12.0)	(3.5, 7.7; 0.7– 1.8)
RI at start of intervention period, median	16	18
(1st, 3rd quartile; min–max)	(0, 55; 0–100)	(0, 42; 0–100)
Red, n (%)	19 (54.3 %)	20 (54.1 %)
Amber, n (%)	5 (14.3 %)	8 (21.6 %)
Green, n (%)	11 (31.4 %)	9 (24.3 %)
No value, n (%)a	1 (2.8 %)	1 (2.6 %)
RASS score at start of intervention period, median	−3	−4
(1st, 3rd quartile; min to max)	(−4, −2; −5 to +0)	(−4, −3; −5 to +2)
Total alfentanil dose, mg, prior to monitoring, median	1.75	3.00
(1st, 3rd quartile; min–max)	(0.75, 5.25; 0.00–14.00)	(1.00, 7.50; 0.00–17.50)

^aOne patient in each group had a long delay in commencing Responsiveness Index (RI) monitoring by clinical staff after randomisation. These two patients were not given a baseline RI value, and were excluded from the subgroup analysis of patients with RI <20 at baseline, as the value was uncertain at the start of the study. APACHE acute physiology and chronic health evaluation, SOFA sequential organ failure assessment, RASS Richmond agitation-sedation scale